Featured Editorial

  1. A Case Study: Control Strategies For A Multi-Dose Pen Injector 4/8/2026

    A case study highlighting the importance of drug and device team alignment on control strategy, defining what to control and which controls can and should be implemented.

  2. Control Strategies For Injectable Drug Delivery Combination Products 4/7/2026

    Defining combination product CQAs across drug and device enables an end-to-end control strategy that improves product quality from the start of development.

  3. From IV To Subcutaneous: It's Not About Convenience, It's About System Design 4/6/2026

    IV→SC transition extends beyond dose, volume, concentration, and device; it requires integrated system design, not a series of isolated optimizations.

  4. Beyond Biologics: A Biophysical Approach To Crohn's Disease 4/2/2026

    Research into a nano-amorphous approach suggests a new breakthrough in Crohn’s management may come from a shift toward modulating the biophysical environment of the gut.

  5. 6 Packaging And Delivery Challenges For Biologic Therapies 4/1/2026

    In this article, Fran DeGrazio identifies six aspects of biologics-based therapy packaging and delivery that, if addressed, may help to ensure successful product development and lifecycle management. They include 1) chemical compatibility with device functionality, 2) long-acting formulations, 3) product stability, 4) primary packaging and device integration, 5) cold storage, and 6) higher concentrations and viscosities. 

  6. Does TSLP Inhibition Signal The Next Wave Of Respiratory Biologics? 4/1/2026

    Thymic stromal lymphopoietin (TSLP) inhibition has firmly established itself as a strategy in respiratory disease. This article highlights some promising drug candidates and next-generation approaches.

  7. Nanosystems And Rare Diseases: Opportunities And Limitations 3/27/2026

    Nanosystems offer unique capabilities, enabling researchers to design precise, versatile delivery systems that address key challenges in rare diseases.

  8. 3 Emerging Trends In Drug Delivery Device Pipelines 3/18/2026

    When analyzing the drug delivery product pipeline, three key technologies stand out. Check out the latest market research.

  9. Organic Impurities: New Draft ICH Q3E Guidance For Leachables And Extractables 3/17/2026

    A new draft guidance document from ICH, issued jointly with the EMA, adopts the position that the assessment of leachables and extractables requires a holistic framework for risk evaluation.

  10. Closing The Adherence Gap: The Connected Health Era 3/13/2026

    Connected health is shifting healthcare from reactive to proactive by enabling providers to oversee drug delivery while allowing patients to actively engage in their care.